




<b>Name</b>	<b>John F. DiPersio, M.D., Ph.D.</b>	
<b>Current Position</b>	<b>Director, Center for Gene and Cellular Immunotherapy</b>	
<b>Country</b>	<b>United States</b>	
<b>Major Field</b>	<b>Oncology</b>	

## Educational Background

1973 - Williams College, BA Biology

1980 - University of Rochester, MD, PhD, Microbiology

1980-81 - Intern, Parkland Memorial Hospital, The University of Texas Southwestern Medical Center, Dallas, TX

1981-83 - Resident, Parkland Memorial Hospital, Dallas, TX

1983-84 - Chief Resident, Parkland Memorial Hospital, Dallas, TX

1984-87 - Fellow, Division of Hematology/Oncology, UCLA School of Medicine

## Professional Experience

2022 – present	Director, Section of Cellular Therapy, Division of Oncology, Washington University School of Medicine, St Louis, MO.
2020 – present	Associate Director, Bursky Center for Human Immunology and Immunotherapy Programs (CHiIPs), WUSM.
2017 – present	Director, Center for Gene and Cellular Immunotherapy, Division of Oncology, Washington University School of Medicine, St Louis, MO
2006 – 2011	Scientific Director, Good Manufacturing Procedure (GMP) Facility; Siteman Cancer Center
2000 – 2022	Chief, Division of Oncology, Washington University School of Medicine, St. Louis, MO
2000 – 2006	Director, Section of BMT and Leukemia, Washington University School of Medicine, St. Louis, MO
2000 – 2022	Deputy Director, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
1997 – 2000	Acting Director, Medical Oncology, Washington University School of Medicine, St. Louis, MO
1997 – Present	Professor of Medicine, Pediatrics and Pathology/Immunology, Washington University School of Medicine, St. Louis, MO
1994 – 2000	Chief, Division of Bone Marrow Transplantation and Stem Cell Biology, Washington University School of Medicine, St. Louis, MO
1994 – 1997	Associate Professor of Medicine, Pediatrics and Pathology, Washington




---

1990 – 1994	University School of Medicine, St. Louis, MO
1990 – 1994	Assistant Professor of Medicine, Hematology Unit, University of Rochester School of Medicine, Rochester, New York
1990 – 1994	Director, Bone Marrow Transplant Program, Strong Memorial Hospital, Rochester, NY
1990 – 1994	Assistant Professor of Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY
1988 – 1990	Assistant Professor of Medicine, Division of Hematology-Oncology, UCLA School of Medicine, Los Angeles, CA
1987 – 1988	Instructor of Medicine, Division of Hematology-Oncology, UCLA School of Medicine, Los Angeles, CA

---

## Other Experience and Professional Memberships

1993	Member, Editorial Board <u>Journal of Experimental Hematology</u>
1995	Member, Nominating Committee, International Society for Experimental Hematology
1997	Chairman, Nominating Committee, International Society for Experimental Hematology (ISEH)
1997	Member, Stem Cell Evaluation Committee, International Society for Hematotherapy and Graft Engineering (ISHAGE)
1997	Councilor, International Society of Experimental Hematology
1998	Member, Barnard Free Skin and Cancer Board of Directors
1998	Guest Editor, <u>Blood Journal</u>
1999-2006	Member, External Advisory Panel, M.D. Anderson, (MDACC) PPG-AML
1999	Deputy Director, Siteman Cancer Center, Washington University School of Medicine
2000-06	Leukemia and Lymphoma Society of America, Career Development Award Study Section Member
2000	Chairman, NHLBI Consensus Conference on Allo Transplantation for Non-Malignant Diseases
2001	ISHAGE Meeting. First prize, Scientific Merit: "Control of GvHD using genetically modified T cells."
2002	Member, Executive Committee IBMTR/ABMTR
2003-06	Award Member, ASH Committee on Educational Affairs, Washington D.C.
2003-06	Member, Board of Directors, American Society of Biology and Marrow Transplant.
2004-09	NCI (NIH) Permanent member CONC Study Section Member
2005	Chairman, Study Section RFA HL-04-017 (NHLBI) Spec. Ctr. for Cell Based Therapy.
2006	NIH (ZRG)/CSR – Gene Therapy and Inborn Errors – Special Emphasis Review Panel
2006	Member, ASH Committee on Gene and Cell Therapy
2007-12	Co-Chair, CIBMTR Acute Leukemia Working Committee
2008	NCI P01 Special Emphasis Panel ZCA1-RPRB-J, October 2008, Bethesda MD
2008-	ASH Scientific Committees on Cell and Gene Therapy and Hematopoiesis
2008-11	Member, Scientific and Medical Research Funding; California Instit Regen. Med (CIRM)
2009	Member, Review Panel; Center Grants, National Medical Research Council, Singapore
2009	Member, ASBMT Committee on Research Priorities
2010	ASH/CRTI Faculty/Mentor
2010	Member, External Advisory Board, Cancer Therapy and Research Center, UT San Antonio

---




---

2010	Chairman, NIH NIAID ZAI1 MFH-01 P01 Special Emphasis Panel
2011	NIH (BST-M)/CSR- Special Emphasis Panel
2011	Study Section, Doris Duke Center Grants for Sickle Cell Disease
2011	Chairman, NIH/NIDDK P01 Special Emphasis Panel, Methylation and Hematopoiesis
2012-	Vice Chair (2012-13) and Chair (2013-14) ASH Scientific Committee on Hematopoiesis
2012-	NIH Study Section for Loan Repayment Program
2012-	EAB member, University of Michigan Cancer Center
2013	Member, NCI Provocative Questions B Study Section
2013	EAB member, Levine Cancer Institute
2014-19	Study Section Member CPRIT (Cancer Prevention Research Institute of Texas)
2013-19	Member, Board of Scientific Councilors, National Cancer Institute (NCI)
2014	CIRM Working Group 2.0 – Permanent Member
2014-	EAB member, University of Chicago
2015	American Cancer Society, National Board of Directors for Hope Lodges
2015	Medical Advisory Board; Gabrielle's Angel Foundation for Cancer Research
2015-	EAB member, Sylvester Comprehensive Cancer Center, University of Miami
2015-17	Member, AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research Scientific Research Committee
2016	Chair, Data Safety Monitoring Committee (DSMC) BL-8040 and Nivolumb for the Treatment of Pancreatic Cancer (Bioline)
2016	Chair, DSMC Dana Farber/Boston Childrens Hospital "Use of Plerixafor for Stem Cell Mobilization in Patients with Sickle Cell Disease"
2016-19	Member, AACR Science Policy and Government Affairs Committee (SPGAC)
2017	Review Committee Member, NIH Pioneer Award
2017	Director, Center for Gene and Cellular Immunotherapy (CGCI), Washington University
2017-21	Member, ASH Honorific Award and ASH Mentor Award Committee
2017-19	Chair, for the Finneran Prize Awardee, MDACC
2018	Leukemia and Lymphoma Society New Idea Award Committee member
2018	NIH/NCI Cancer Moonshot Human Tumor Atlas Study Section ZRG1 OTC-T
2018	EAB member, DFCI Leukemia SPORE
2018-	EAB member, University of Rochester
2018-	EAB member, Weill Cornell Medicine
2018-	Member AACR Honorific Awards Committee
2019	Member Scientific Committee, 2019 Acute Leukemias SVII, Munich Germany
2019-	Member Dana Farber Cancer Institute (DFCI) External Advisory Board
2019-	Member EAB of DFCI Leukemia SPORE
2019-	Member EAB of MSKCC Leukemia SPORE
2020-	Member EAB Mt Sinai PPD in Stem Cell Transplantation
2020-	Member EAB O'Neal CCC at University of Alabama at Birmingham
2020-	Member EAB Case CCC
2020-	Member EAB DFCI Department of Medical Oncology
2021	City of Hope national Medical Center CCC EAB member
2022	Chair, AACR Hematologic Malignancies Research Grants Scientific Review Committee
2022	FDA, Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC)
2022	Member, AACR Task Force of Hematologic Malignancies

---

## Main Scientific Publications



1. Persaud SP, Ritchey JK, Kim S, Lim S, Ruminski PG, Cooper ML, Rettig MP, Choi J, **DiPersio JF**. Antibody Drug Conjugates plus Janus Kinase Inhibitors Enable MHC-mismatched allogeneic hematopoietic stem cell transplantation. *J Clin Invest*. 131(24): e145501, 2021. PMID: 34730109
2. Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, Rettig MP, Wang B, Eissenberg LG, Ghobadi A, Gehrs LN, Prior JL, Achilefu S, Miller CA, Fronick CC, O'Neal J, Gao F, Weinstock DM, Gutierrez A, Fulton RS, and **DiPersio JF**. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. *Leukemia* 2018. 32:1970-1983 PMID: [PMC29483708](https://pubmed.ncbi.nlm.nih.gov/3029483708/)
3. Kim MY, Cooper ML, Jacobs MT, Ritchey JK, Holloway J, Fehniger TA, **DiPersio JF**. CD7-deleted hematopoietic stem cells can restore immunity after CART cell therapy. *JCI Insight*, 2021 Aug 23;6(16):3149819. PMID: 34423790
4. Kim MY, Jayasinghe R, Devenport JM, Ritchey JK, Rettig MP, O'Neal J, Staser KW, Kennerly KM, Carter AJ, Gao F, Lee BH, Cooper ML, John F. **DiPersio JF**. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence and anti-tumor activity. *Nat. Comm.*, 2022, In Press.
5. Rimando JC, Chendamarai E, Rettig MP, Jayasinghe RG, Christopher M, Ritchey JK, Christ S, Kim M, Bonvini E, **DiPersio JF**. Flotetuzumab and other T-Cell Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells. *Blood*. 2023: blood.2022017795. doi: 10.1182/blood.2022017795. Online ahead of print. PMID: 36563336.
6. Eissenberg LG, Rettig MP, Ritchey JK, Prior JL, Schwarz SW, Frye J, White BS, Fulton RS, Ghobadi A, Cooper ML, Couriel DR, Seegulam ME, Piwnica-Worms D, Dehdashti F, Cornetta K, **DiPersio JF**. [18F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. *Mol Ther*. 2015 Mar 25. PMID: [PMC4817759](https://pubmed.ncbi.nlm.nih.gov/25817759/).
7. Christopher, MJ, Petti, AA, Rettig, MP, Miller, CA, Chendamarai, E, Duncavage, EJ, Klco, JM, Helton, NM, O'Laughlin, M, Fronick, CC, Fulton, RS, Wilson, Wartman, LD, Welch, JS, Heath, SE, Baty, JD, Payton, JE, Graubert, TA, Link, DC, Walter, MJ, Westervelt, P, Ley, TJ, **DiPersio, JF**. Immune escape of relapsed AML cells after allogeneic transplantation. *N Engl J Med*, 2018. doi:10.1056/NEJMoa1808

Complete List of Published Work in MyBibliography (>450publications): <https://www.ncbi.nlm.nih.gov/myncbi/john.dipersio.1/bibliography/public/>